4.08  -0.07 (-1.69%)		09-25 16:00
Open: 4.18 High: 4.18 Volume: 1,034,969		Pre. Close: 4.15 Low: 4.02 Market Cap: 405(M)

Short term
Mid term
Targets	6-month :	6.21	1-year :	7.14
Resists	First :	5.31	Second :	6.11
Pivot price	4.56
Supports	First :	4.01	Second :	3.34
MAs	MA(5) :	4.24	MA(20) :	4.88
	MA(100) :	7.06	MA(250) :	8.48
MACD	MACD :	-0.5	Signal :	-0.5
%K %D	K(14,3) :	4	D(3) :	8.4
RSI	RSI(14): 29.8
52-week	High :	13.14	Low :	4.01

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SPRY ] has closed above bottom band by 25.8%. Bollinger Bands are 9.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	4.19 - 4.21	4.21 - 4.23
Low:	3.96 - 3.99	3.99 - 4.02
Close:	4.04 - 4.09	4.09 - 4.12

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.

Fri, 25 Sep 2026
Class Action Filed Against ARS Pharmaceuticals, Inc. (SPRY) Over Securities Violations - Contact Levi & Korsinsky Today - ACCESS Newswire

Fri, 25 Sep 2026
Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Deadline on October 5, 2026 - barchart.com

Fri, 25 Sep 2026
Robbins LLP Reminds SPRY Stockholders of the Pending - GlobeNewswire

Fri, 25 Sep 2026
SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today - stocktwits.com

Fri, 25 Sep 2026
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with ... - Black Hills Pioneer

Thu, 24 Sep 2026
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	99 (M)
Shares Float	48 (M)
Held by Insiders	16.1 (%)
Held by Institutions	92 (%)
Shares Short	22,950 (K)
Shares Short P.Month	22,670 (K)

EPS	-2.19
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.12
Profit Margin	-184.3 %
Operating Margin	-182.7 %
Return on Assets (ttm)	-48.1 %
Return on Equity (ttm)	-210.4 %
Qtrly Rev. Growth	114.1 %
Gross Profit (p.s.)	0.68
Sales Per Share	1.17
EBITDA (p.s.)	-2.16
Qtrly Earnings Growth	0 %
Operating Cash Flow	-196 (M)
Levered Free Cash Flow	-118 (M)

PE Ratio	-1.88
PEG Ratio	0
Price to Book value	31.38
Price to Sales	3.47
Price to Cash Flow	-2.07

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.